Ansella Therapeutics is a specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes, with a focus on vaginal health conditions. The company applies detailed understanding of well-known biological systems to develop treatments that address often overlooked areas of women's health.

Avery Therapeutics is a company dedicated to developing tissue-engineered therapeutics to treat diseases and injuries to human muscle. A startup spun out of the University of Arizona, the company is advancing first-in-class immunomodulatory therapeutics to redirect the immune system to address diseases of aging and inflammation.

Beacon Biomedical Inc. is a CLIA-accredited proteomic diagnostics laboratory focused on developing and commercializing laboratory-developed tests, including a diagnostic device designed to detect colorectal cancer in its early stages. The company raised $1.47M and was later acquired by CashLabs LLC in 2022.

BioSpeedia is a biotechnology company founded by two scientific researchers from Institut Pasteur, focused on the production of diagnostic test kits for infectious diseases. The company develops rapid, validated diagnostic solutions leveraging deep scientific expertise from one of the world's leading biomedical research institutions.

Blackrock Neurotech is a neurotechnology company focused on developing implantable brain-computer interfaces (BCIs) to help people with neurological conditions regain lost function. The company brings together engineers, neuroscientists, and clinicians and has partnered with Cognixion to supply its technology for wearable neural interface platforms.

Calimmune, Inc. was a clinical-stage gene therapy company that developed and commercialized lentiviral gene therapies for sickle cell disease and beta-thalassemia, including its lead asset CAL-H using the Select+™ stem cell gene therapy platform. The company was acquired by CSL Behring in 2017.

Cancer Prevention Pharmaceuticals, Inc. is a clinical-stage company developing therapeutics designed to reduce the risk and recurrence of cancer and rare diseases. The company was acquired by Panbela Therapeutics (Nasdaq: PBLA) in June 2022.

Duo Oncology is a cancer medicine company developing next-generation chemotherapy for solid tumors using ultrasmall, tumor-penetrating nanomedicines that deliver drug combinations to deep tumors. Its lead program, DUO-207, is designed to improve on existing chemotherapy approaches. The company is backed by BeOne and brings together clinical oncologists and pharmaceutical scientists.

Enquyst Technologies is a biotechnology company disrupting the way biological drugs are manufactured through next-generation bioprocess and analytical technologies. The early-stage company is focused on developing innovative, pathbreaking tools to improve the efficiency and quality of biopharmaceutical production.

EVQLV is a biotechnology company that leverages advances in computation to accelerate the design and development of therapeutic antibodies. Its proprietary computational platform generates diverse, fully-human antibodies, aiming to accelerate the speed that healing reaches patients. The company's platform is designed to make AI accessible to antibody scientists.

GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world's most important bacterial pathogens, including pneumococcal bacteria. The company is developing a universal pneumococcal vaccine aimed at providing broader and more durable protection than existing options.

GT Medical Technologies is a medical device company focused on radiation therapy for brain tumor patients. Its GammaTile product is a surgically implantable, bioabsorbable tile-based radiation therapy placed directly into the tumor cavity at the time of tumor resection, and has received FDA 510(k) clearance for all types of recurrent and newly diagnosed malignant brain tumors. In June 2026, the company completed an oversubscribed $100 million Series E financing.

Healionics is a biomedical company focused on engineered biomaterials that provide safer and more reliable means of bloodstream access for dialysis in patients with kidney failure. The company also spun out iSTAR Medical, which developed the MINIject glaucoma device.

High Throughput Genomics (HTG), based in Tucson, Arizona, was a molecular diagnostics company founded in 1997 that developed a universal platform for gene expression profiling, miRNA and mRNA measurement. The company later rebranded as HTG Molecular Diagnostics and went public; it subsequently filed for Chapter 11 bankruptcy. HTG was backed by Desert Angels and other investors in the Arizona life sciences ecosystem.

Immunis Biomedical is a clinical-stage private biotechnology company developing novel secretome-based biologics for age-related immune dysfunction and disease. The company has developed a proprietary method to isolate clinical-grade, multi-active stem cell-derived products targeting age-driven diseases and has been recognized as a leader in its field.

Integrated Molecular Innovations develops biowearable devices that continuously monitor hormone levels in interstitial fluid, using a proprietary polymer chemistry and hollow microneedle array to non-invasively monitor thyroid hormones. Spun out of Michigan Technological University; 2024 ASU Innovation Open finalist.

iQure Pharma is a clinical-stage biotechnology company developing first-in-class astrocyte-targeted therapeutics for CNS disorders. The company's approach focuses on restoring glutamate homeostasis to break the cycle of excitotoxicity, targeting conditions where glutamate imbalance drives neurological damage.

LightDeck Diagnostics was a Boulder, Colorado-based medical device company that enabled lab-quality rapid diagnostic tests to be run at the point of need. The company was acquired by Heska Corporation for approximately $38.7 million in 2023 and is now part of Antech Diagnostics.

NeoLight LLC is a medical device company headquartered in Scottsdale, Arizona, focused on neonatal care. It develops the Skylife Neonatal Phototherapy System and offers the Phoenix CONNECT communication platform for retinopathy of prematurity (ROP) screening, empowering healthcare professionals with tools for newborn care.